The EBOV positive control animals showed clinical signs consistent with the four rhesus macaques in the pilot study above (tables S2 and S3) and exhibited similar deviations in hematological and serum chemistry parameters compared to baseline (day of challenge) values, i.e., lymphocytopenia, thrombocytopenia, and elevated markers of hepatic injury (e.g., ALT and AST) and acute systemic inflammation (CRP) (table S3). This evidence concerns the gene GPT and Thrombocytopenia.